In cancer treatment, there is a narrow therapeutic window with chemotherapy agents. The most common reason for chemotherapy dose reduction is neutropenia resulting in impaired survival. Chemotherapy dosage is calculated based on body surface area, with no adjustment recommendation for a patient's albumin level even though chemotherapy medications are highly protein-bound. The insight gained by mathematical modeling suggests an altered free/bound drug ratio in patients with low albumin results in severe side effects. Furthermore, mathematical modeling also reveals impaired survival in dose-reduced chemotherapy patients may be from decreased bound drug levels while free drug levels remain unchanged. Restoring the free/bound drug ratio by correcting a patient's albumin deficit will reduce chemotherapy side effects and improve patient outcomes. Finally, enhanced chemotherapy treatment is possible by capping the free drug level and maximizing the bound drug level. The mathematical model predicts the following chemotherapy medications will have altered free/bound drug ratio in patients with low albumin: cisplatin, oxaliplatin, doxorubicin, epirubicin, idarubicin, paclitaxel, eribulin, etoposide, vinorelbine, bendamustine, chlorambucil, and pemetrexed.